title: Enhanced circulating soluble LR11 in patients with diabetic retinopathy.
abstract: OBJECTIVE
  To investigate the relationship of circulating levels of soluble form of LR11 (sLR11; also called SorLA or SORL1), with the progression of proliferative diabetic retinopathy (PDR) in patients with type 2 diabetes mellitus.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Fifty-four patients with type 2 diabetes mellitus were divided into 2 sex- and age-matched groups: one with PDR (n = 29) and the other with nonproliferative diabetic retinopathy (n = 25). The serum sLR11 levels were measured with an immunodetection system followed by chemifluorescence quantification.
  
  
  RESULTS
  The serum sLR11 levels were higher in the PDR group than in the nonproliferative diabetic retinopathy group (5.8 ± 1.2 U vs 3.7 ± 1.3 U; P < .01). A multivariate regression analysis showed that circulating sLR11 is a factor contributing to the prediction of PDR independent of other classical risk factors, and an area under the receiver operating characteristic curve analysis revealed that the sensitivity and the specificity were equivalent to or more than those of other factors. Among the classical risk factors for PDR, glycosylated hemoglobin levels showed the highest correlation coefficient (P < .01) for the sLR11 concentrations.
  
  
  CONCLUSIONS
  Serum sLR11 concentration may reflect the progression of PDR in patients with type 2 diabetes mellitus. sLR11, released from immature vascular cells and indicating the development of atherosclerosis, is expected to be a novel candidate biomarker indicating diabetic retinopathy in patients with type 2 diabetes mellitus.
authors.affiliation: Cardiovascular Center, Sakura Hospital Medical Center, Toho University, Chiba, Japan. takahashi-04@sakura.med.toho-u.ac.jp
authors.forename: Mao
authors.initials: M
authors.lastname: Takahashi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Bujo
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Shiba
authors.forename: Meizi
authors.initials: M
authors.lastname: Jiang
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Maeno
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
mesh_terms: D000368:Aged; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D003930:Diabetic Retinopathy / Q000097:blood*; D018450:Disease Progression; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D026502:LDL-Receptor Related Proteins / Q000097:blood*; D008163:Luminescent Measurements; D008297:Male; D026901:Membrane Transport Proteins / Q000097:blood*; D008875:Middle Aged; D012372:ROC Curve; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D026502:LDL-Receptor Related Proteins; D026901:Membrane Transport Proteins; C102582:SORL1 protein, human; C517652:hemoglobin A1c protein, human